Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Shire Plc Ads (SHPG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 43,825,008
  • Shares Outstanding, K 300,810
  • Annual Sales, $ 11,397 M
  • Annual Income, $ 327,400 K
  • 36-Month Beta 1.60
  • Price/Sales 2.96
  • Price/Cash Flow 8.91
  • Price/Book 1.34

Price Performance

See More
Period Period Low Period High Performance
1-Month
141.82 +2.24%
on 01/18/18
159.38 -9.03%
on 01/02/18
-12.66 (-8.03%)
since 12/19/17
3-Month
137.17 +5.70%
on 11/13/17
160.37 -9.59%
on 12/19/17
-2.83 (-1.91%)
since 10/19/17
52-Week
137.17 +5.70%
on 11/13/17
192.15 -24.54%
on 05/18/17
-19.12 (-11.65%)
since 01/19/17

Most Recent Stories

More News
Nektar Boasts Strong Pipeline, Competition Remains a Woe

Nektar (NKTR) impresses with a strong pipeline of early and late-stage candidates. The company makes a significant progress with its lead candidate, Onzeald, for advanced breast cancer in adults.

AZN : 35.44 (+1.06%)
LLY : 85.49 (-0.38%)
SHPG : 144.99 (-0.48%)
NKTR : 71.59 (+2.04%)
The Best Intranet Solution to Evolve With Your Company - Powell Software Looks Back at 2017

2017 was a year of strong growth and innovation for Powell Software and its digital workplace solution, Powell 365. Powell Software tripled its license revenue, doubled its customer base and extended its...

DGX : 103.06 (+1.47%)
SHPG : 144.99 (-0.48%)
Allergan's (AGN) Sales Guidance for 2018 Lower Than Expected

Allergan (AGN) announces weaker-than-expected sales outlook for 2018. A generic version of Restasis is expected to be launched in Q2.

MYL : 46.73 (+0.47%)
AGN : 181.33 (+0.94%)
SHPG : 144.99 (-0.48%)
SGYP : 2.40 (+5.73%)
Shire Announces Business Update at 36th Annual J.P. Morgan Healthcare Conference

Shire Announces Business Update at 36th Annual J.P. Morgan Healthcare Conference

JPM : 113.01 (-0.22%)
SHPG : 144.99 (-0.48%)
Allergan to Cut Jobs Amid Loss of Exclusivity for Key Drugs

Allergan (AGN) is laying off over 1,000 employees as part of a cost-cutting and restructuring program as it faces potential loss of exclusivity for some of its key products in 2018.

MYL : 46.73 (+0.47%)
AGN : 181.33 (+0.94%)
SHPG : 144.99 (-0.48%)
SGYP : 2.40 (+5.73%)
Shire to present at the 36th Annual J.P. Morgan Healthcare Conference

Shire to present at the 36th Annual J.P. Morgan Healthcare Conference

JPM : 113.01 (-0.22%)
SHPG : 144.99 (-0.48%)
Protalix (PLX) Fabry Disease Candidate Gets Orphan Status

Protalix BioTherapeutics's (PLX) pipeline candidate, PRX-102, gets orphan drug status in Europe which is being developed as a treatment for Fabry disease.

SHPG : 144.99 (-0.48%)
PLX : 0.71 (+1.72%)
PFE : 36.94 (-0.14%)
SNY : 44.60 (+0.20%)
Shire files for FDA approval of a new plasma manufacturing facility in Covington, Georgia to support growing Immunology franchise

Shire files for FDA approval of a new plasma manufacturing facility in Covington, Georgia to support growing Immunology franchise

SHPG : 144.99 (-0.48%)
What's Happening With These Drug Makers Stocks? -- Immune Pharmaceuticals, Zogenix, Shire, and Merck

In keeping with the commitment to dynamically provide members with timely information, WallStEquities.com has issued free tailored Stock Review on IMNP, ZGNX, SHPG, and MRK which is a click away at www.wallstequities.com/registration....

IMNP : 0.59 (-1.67%)
MRK : 61.28 (+0.25%)
SHPG : 144.99 (-0.48%)
ZGNX : 35.95 (+1.84%)
Shire's New Formulation of Oncaspar Gets Approval in Europe

Shire's (SHPG) marketing authorization application for a new (dried) formulation of its leukemia drug, Oncaspar receives approval from the European Commission.

CORT : 23.98 (+1.70%)
CLDX : 2.76 (+0.73%)
SHPG : 144.99 (-0.48%)
ACAD : 26.92 (-3.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Shire Pharmaceuticals Group plc is a specialty pharmaceutical company focused primarily on two therapeutic areas: central nervous system disorders and metabolic bone diseases. (press release)

See More

Key Turning Points

2nd Resistance Point 147.37
1st Resistance Point 146.18
Last Price 144.99
1st Support Level 143.67
2nd Support Level 142.35

See More

52-Week High 192.15
Fibonacci 61.8% 171.15
Fibonacci 50% 164.66
Fibonacci 38.2% 158.17
Last Price 144.99
52-Week Low 137.17

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.